For many people with type 2 diabetes, the hard part of insulin is not the science — it is the calendar. A shot every single day is easy to postpone when life gets busy, and delayed starts can cost years of healthier blood sugar.
The FDA has approved Eli Lilly’s Onswik (insulin efsitora alfa-gobe), a once-weekly basal insulin for adults with type 2 diabetes, used with diet and exercise to help control high blood sugar. Lilly says the design can cut injections by more than 300 a year versus once-daily basal insulin — roughly 52 shots a year instead of about 365.
Approval rests on the Phase 3 QWINT program in more than 3,400 adults. Across those trials, weekly Onswik matched the A1C drop of daily insulin glargine or degludec, with a broadly similar overall safety profile. It is not for type 1 diabetes, where severe hypoglycemia risk is higher. Common side effects include low blood sugar, injection-site reactions, and others listed on the label. The Onswik KwikPen is expected in the U.S. in the coming months.
This is Lilly’s fourth major nod for the drug after Europe, Mexico, and Japan, and the second once-weekly basal insulin available in the U.S. after Novo’s Awiqli — more choice for patients and clinicians who have been waiting for a weekly basal option.
Why regular people should care
Fewer needle days can mean more people actually start and stick with basal insulin when their doctor recommends it. That is not a miracle cure; it is a practical lifestyle unlock for a disease that already asks a lot of daily attention. If you or someone you love has been putting off insulin because of the every-day grind, a weekly option is worth a conversation with a clinician — not a DIY switch.
What’s next
Watch U.S. availability timing, insurer coverage, and how Onswik and Awiqli share the once-weekly basal market. For millions managing type 2 diabetes, the win is simple: one less daily chore between them and steady coverage.
Sources: Lilly / PR Newswire, Medscape.